Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
17 févr. 2021 08h38 HE
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...
Global Checkpoint Inhibitors Market Report 2020-2030: COVID-19 Growth and Changes
22 déc. 2020 05h23 HE
|
Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
Immune Checkpoint Inhibitors Market, 2025
30 oct. 2020 04h53 HE
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The...
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
17 sept. 2020 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
13 nov. 2017 08h30 HE
|
Galectin Therapeutics Inc.; Providence Cancer Institute
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...
PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA
18 oct. 2017 09h38 HE
|
Provectus Biopharmaceuticals Inc.
– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...
Liquid Biopsy Tools, Diagnostics Market to Reach $4.5B by 2022
10 oct. 2017 15h45 HE
|
BCC Research
WELLESLEY, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Liquid biopsy is rapidly gaining traction as a supplement or alternative to tissue biopsy, with the potential to attain a global market value of...
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
23 févr. 2017 09h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...